Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hopital Charles Nicolle | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objectives of the study are:
o Objective ultrasound: Determine the presence or absence of subclinical DVT in practicing ultrasound-Doppler Day7 and Day35, patients who underwent TKA or THA
o Clinical objective To evaluate the efficacy and tolerability clinical Enox ® in these patients compared with the original drug Lovenox ®.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| lovenox | Active Comparator | patient under lovenox 4000 IU |
|
| enoxa | Active Comparator | patients under Enoxa 4000 IU |
|
| total knee replacement | No Intervention | patients undergoing total knee replacement | |
| total hip replacement | No Intervention | patient undergoing total knee replacement |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Enoxaparin | Drug | enoxaparin 4000 IU 1 injection/day in subcutaneous. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Presence or absence of ultrasound findings in favor of asymptomatic DVT | After orthopedic surgery, patients are put under LMWH thromboprophylaxis based but some patients may be carrying an asymptomatic DVT. so we'll try the distal venous thrombosis rate in these patients using Doppler ultrasound. | Day 7 and 35 |
| Measure | Description | Time Frame |
|---|---|---|
| To evaluate the efficacy and tolerability clinical Enox ® in these patients. | Criteria for evaluating the effectiveness of Enox ®:
| 3 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| mondher kooli, MD | Hospital Charles Nicolle | Study Chair |
| Ramzi Bouzidi, MD | Hospital Charle Nicolle | Principal Investigator |
| Mustapha Azaiz, MD | Delta Medical Center | Principal Investigator |
| Abdelaziz Zarrouk, MD | Hospital Charles Nicollle | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Hospital Charle Nicolle | Tunis | Tunis BAB Souika | 1006 | Tunisia |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| Result | 1- Physiopathologie et prévention de la maladie thromboembolique veineuse postopératoire. Charles Marc Samama, Pierre Albaladejo. Sang Thrombose Vaisseaux 2008 ; 20, n°3 :138-43 2- Thromboses veineuses profondes. Dr Jean - Marc Schleich. Département de cardiologie et maladies vasculaires ; CHU de Rennes ; mis à jour le 6 septembre 1998 3- Prévention de la Thrombose veineuse. Dr H. Raybaud - MAJ 2006. Esculape.com : site de médecine générale. 4- Thrombose veineuse profonde. J. - L. Bosson, A. Franco. 1995 SIIM CHU de Grenoble 5- Suivi écho-doppler de thromboses veineuses profondes distales asymptomatique. M.-T BARRELLIER et col. Journal des maladies vasculaires. Masson, 2000, 25, 3 195-200. 6- 83ème Réunion annuelle de la société française de chirurgie orthopédique et traumatologique. Résumé des communications. Revue de chirurgie orthopédique et réparatrice de l'appareil moteur (2008) 94S, S231-S327. |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D020246 | Venous Thrombosis |
| ID | Term |
|---|---|
| D013927 | Thrombosis |
| D016769 | Embolism and Thrombosis |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D017984 | Enoxaparin |
| ID | Term |
|---|---|
| D006495 | Heparin, Low-Molecular-Weight |
| D006493 | Heparin |
| D006025 | Glycosaminoglycans |
| D011134 | Polysaccharides |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D002241 |
| Carbohydrates |